Valuation: Red Light Holland Corp.

Market Cap 15.35M 10.85M 9.65M 8.94M 8.14M 1.03B 15.6M 107M 42.14M 538M 40.73M 39.87M 1.71B P/E 2025
-2.98x
P/E 2026 -1.71x
Enterprise Value 7.12M 5.03M 4.47M 4.15M 3.77M 478M 7.23M 49.85M 19.55M 249M 18.89M 18.49M 795M EV / Sales 2025
0.29x
EV / Sales 2026 0.57x
Free-Float
88.33%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer - 22/05/2020
Director of Finance/CFO - 19/08/2026
President 40 -
Director TitleAgeSince
Chairman - 29/09/1982
Chairman - 25/05/2020
Director/Board Member 31 01/03/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 10.85M
-1.58%-1.33%+17.56%+39.99% 48.17B
+3.40%-0.05%-18.81%+14.84% 34.52B
+3.46%+2.35%-17.92%-13.65% 15.17B
-0.92%+0.51%-29.53%-3.35% 10.57B
+0.47%+0.94%-1.83%+12.04% 5.23B
-1.21%-2.98%-20.17%+328.70% 4.6B
+1.98%-2.33%-30.68%-35.79% 4.49B
+1.79%-2.06%-3.72%+3.64% 3.92B
+0.84%+0.61%-10.36%+0.99% 3.52B
Average +0.82%-0.82%-12.83%+38.60% 14.46B
Weighted average by Cap. +0.77%-1.16%-5.21%+27.88%

Financials

2025 2026
Net sales 4.94M 3.5M 3.11M 2.88M 2.62M 332M 5.02M 34.62M 13.57M 173M 13.12M 12.84M 552M 4.2M 2.97M 2.64M 2.44M 2.22M 281M 4.26M 29.37M 11.52M 147M 11.13M 10.89M 468M
Net income -4.04M -2.86M -2.54M -2.35M -2.14M -271M -4.11M -28.3M -11.1M -142M -10.72M -10.5M -451M -6.1M -4.31M -3.83M -3.55M -3.23M -409M -6.2M -42.72M -16.75M -214M -16.19M -15.85M -681M
Net Debt -10.87M -7.68M -6.83M -6.33M -5.76M -729M -11.04M -76.09M -29.83M -381M -28.84M -28.22M -1.21B -8.23M -5.82M -5.17M -4.79M -4.36M -552M -8.36M -57.64M -22.6M -288M -21.84M -21.38M -919M
Projected Income Statement - Annual - Red Light Holland Corp.
Logo Red Light Holland Corp.
Rhelion Life Sciences Corp., formerly Red Light Holland Corp., is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with institutions around the world. PEX010 is its standardized natural psilocybin drug candidate, studied across 80+ clinical trials worldwide, including FDA-authorized programs in depression, PTSD, cancer-related distress, and substance use disorders. Its products also include IBEXX and MB2500. IBEXX is its botanical ibogaine drug candidate. MB2500 is its whole-leaf coca extract drug candidate. It also operates in the Netherlands' legal adult-use market and supports voluntary data collection and research to help advance the scientific understanding of natural psychedelics.
Employees
-